The GOMBS project prepares the commercialization of ultrasensitive point-of-care biosensors for early-stage detection of life-threatening diseases, based on the largest MR effect ever observed at room temperature and small magnetic fields, recently discovered by the PI [Science 341, 257 (2013)]. Target biomolecules are specifically attached to the sensor and magnetic nanoparticle (NP) labels, and electrically detected using this huge MR effect (patent in preparation). We will develop sensors for disease markers such as prostate-specific antigen (prostate cancer), troponin (heart muscle damage) and hypermethylated DNA (several cancers). The PI will make use of his long-standing, fruitful collaborations with organic chemists on magnetic NP synthesis and assembly, and functional organic monolayers. As the most competitive advantages of our sensor technology we identify (1) high selectivity, sensitivity and speed (2) very simple, scalable device concept, (3) robustness against environmental fluctuations (e.g. temperature-, pH-independent), (4) small size (allowing implementation in a bioassay device for multiple target molecules), and (5) low cost price.Recognizing commercial potential and a clear market need, the GOMBS team is highly motivated to start up a new venture for exploitation of the proposed biosensor. We will develop the optimal business strategy with an experienced business executive. We will collect market insights for calculating the feasibility, and for setting up a strategic mode of action. In collaboration with a patent attorney a strategy will be defined that secures IP protection. GOMBS will deliver a technical proof of concept and a comprehensive business plan including presentation of the product and concept, the team, business and IP strategy, business model, market size and dynamics, technical and operational planning, a SWOT analysis, investment need, and financial forecasts. This plan will form the basis for the launch of a spin-off company.